Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Artesunate in Solid Tumors
NCT02353026Phase 1Completed
- Sponsor
- Georgetown University
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of artesunate in solid tumor, sponsored by Georgetown University. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jan 2015; status: completed.
02
Drugs
artesunate
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02353026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353026.